Research programme: haemoglobin-based proteins - Therapure Biopharma

Drug Profile

Research programme: haemoglobin-based proteins - Therapure Biopharma

Alternative Names: Haemoglobin-floxuridine conjugate; Haemoglobin-ribavirin conjugate; HRC-203; TBI-301; TBI-303

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hemosol BioPharma
  • Developer Therapure Biopharma
  • Class Haemoglobins; Monoclonal antibodies; Proteins
  • Mechanism of Action Hepatitis C virus envelope protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in Canada (Parenteral)
  • 31 Mar 2015 Preclinical development is underway in Hepatitis C
  • 13 Sep 2010 This programme is in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top